NO20090986L - Sammensmeltet heterosyklisk derivat og anvendelse derav - Google Patents

Sammensmeltet heterosyklisk derivat og anvendelse derav

Info

Publication number
NO20090986L
NO20090986L NO20090986A NO20090986A NO20090986L NO 20090986 L NO20090986 L NO 20090986L NO 20090986 A NO20090986 A NO 20090986A NO 20090986 A NO20090986 A NO 20090986A NO 20090986 L NO20090986 L NO 20090986L
Authority
NO
Norway
Prior art keywords
heterocyclic derivative
cancer
inhibitor
merged
compound
Prior art date
Application number
NO20090986A
Other languages
English (en)
Inventor
Nozomu Sakai
Shinichi Imamura
Naoki Miyamoto
Takaharu Hirayama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20090986L publication Critical patent/NO20090986L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer et sammensmeltet heterosyklisk derivat som har en potent kinaseinhiberende aktivitet og anvendelse derav. En forbindelse representert ved formelen (I): hvori hvert symbol er som definert i beskrivelsen, unntatt en bestemt forbindelse, eller et salt derav, og et farmasøytisk middel som inneholder forbindelsen eller et prodrug derav, som er en kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, en angiogeneseinhibitor, et middel for profylakse eller behandling av kreft, en kreftvekst inhibitor eller en kreftmetastase suppressor.
NO20090986A 2006-08-04 2009-03-04 Sammensmeltet heterosyklisk derivat og anvendelse derav NO20090986L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006213981 2006-08-04
JP2006331230 2006-12-07
JP2007144072 2007-05-30
PCT/JP2007/065681 WO2008016192A2 (en) 2006-08-04 2007-08-03 Fused heterocyclic derivative and use thereof

Publications (1)

Publication Number Publication Date
NO20090986L true NO20090986L (no) 2009-05-04

Family

ID=38996616

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090986A NO20090986L (no) 2006-08-04 2009-03-04 Sammensmeltet heterosyklisk derivat og anvendelse derav

Country Status (18)

Country Link
US (4) US8044049B2 (no)
EP (1) EP2049541B1 (no)
JP (1) JP5238697B2 (no)
KR (1) KR20090047509A (no)
AR (1) AR062207A1 (no)
AU (1) AU2007279595A1 (no)
BR (1) BRPI0714665A2 (no)
CA (1) CA2659971A1 (no)
CL (1) CL2007002261A1 (no)
CO (1) CO6150183A2 (no)
CR (1) CR10607A (no)
IL (1) IL196799A0 (no)
MA (1) MA30651B1 (no)
MX (1) MX2009001349A (no)
NO (1) NO20090986L (no)
PE (1) PE20080538A1 (no)
TW (1) TW200817409A (no)
WO (1) WO2008016192A2 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
UY31676A1 (es) 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
WO2009136663A1 (en) * 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
JP2012504591A (ja) 2008-10-02 2012-02-23 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
MX2011006219A (es) 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
US8637678B2 (en) 2008-12-24 2014-01-28 Syngenta Limited Methods for the preparation of aryl amides
MX2011008452A (es) 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2563792B1 (en) 2010-04-28 2014-08-27 Bristol-Myers Squibb Company Imidazopyridazinyl compounds and their uses for cancer
WO2012135781A1 (en) * 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP2992112B1 (en) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
HK1223307A1 (zh) * 2013-05-30 2017-07-28 Kala Pharmaceuticals, Inc. 新型化合物和其用途
EP3077393A1 (en) * 2013-12-06 2016-10-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
UA119759C2 (uk) 2013-12-13 2019-08-12 Єврокем Агро Гмбх Суміш добрив, яка містить інгібітор нітрифікації
US10253045B2 (en) 2014-11-26 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
US20180028667A1 (en) * 2014-12-10 2018-02-01 Senju Pharmaceutical Co., Ltd. Aqueous liquid agent
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US20190152992A1 (en) 2016-06-29 2019-05-23 Orion Corporation Benzodioxane derivatives and their pharmaceutical use
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110177581B (zh) * 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
DE102017201608A1 (de) 2017-02-01 2018-08-02 Eurochem Agro Gmbh 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP7344971B2 (ja) 2019-09-12 2023-09-14 日本農薬株式会社 置換シクロプロパンオキサジアゾール基を有するイミダゾピリダジン化合物又はその塩類を有効成分とする農園芸用殺虫剤又は動物用の外部若しくは内部寄生虫防除剤並びに該使用方法
WO2021075477A1 (ja) * 2019-10-16 2021-04-22 国立大学法人京都大学 運動神経細胞変性阻害剤
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116456818B (zh) 2020-09-30 2025-12-05 住友化学株式会社 杂环化合物和含有该杂环化合物的有害节肢动物防除组合物
WO2022192732A1 (en) * 2021-03-12 2022-09-15 Gt Molecular, Llc Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024088379A1 (zh) * 2022-10-27 2024-05-02 香港科技大学 肿瘤的治疗或预防方法
WO2025086243A1 (zh) * 2023-10-27 2025-05-01 深圳湾实验室坪山生物医药研发转化中心 白细胞受体酪氨酸激酶抑制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001478A1 (en) 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
WO1989001333A1 (en) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE356117T1 (de) 1999-01-22 2007-03-15 Kirin Brewery Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
BRPI0418328A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd controle de parasitas em animais pelo uso de derivados de imidazo [1,2-b]piridazina
JP4935357B2 (ja) * 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND

Also Published As

Publication number Publication date
BRPI0714665A2 (pt) 2012-03-13
TW200817409A (en) 2008-04-16
US8034812B2 (en) 2011-10-11
WO2008016192A3 (en) 2008-05-08
US8044049B2 (en) 2011-10-25
CA2659971A1 (en) 2008-02-07
US20100273788A1 (en) 2010-10-28
IL196799A0 (en) 2009-11-18
MX2009001349A (es) 2009-04-17
AU2007279595A1 (en) 2008-02-07
KR20090047509A (ko) 2009-05-12
JP2009545583A (ja) 2009-12-24
PE20080538A1 (es) 2008-06-18
US20090306374A1 (en) 2009-12-10
EP2049541B1 (en) 2015-09-23
WO2008016192A2 (en) 2008-02-07
US8273741B2 (en) 2012-09-25
AU2007279595A2 (en) 2009-03-19
MA30651B1 (fr) 2009-08-03
CL2007002261A1 (es) 2008-05-02
CO6150183A2 (es) 2010-04-20
EP2049541A2 (en) 2009-04-22
AR062207A1 (es) 2008-10-22
JP5238697B2 (ja) 2013-07-17
US20100168424A1 (en) 2010-07-01
CR10607A (es) 2009-03-12
US20090137595A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
NO20090986L (no) Sammensmeltet heterosyklisk derivat og anvendelse derav
NO20081454L (no) Met-kinaseinhibitorer
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
MX378499B (es) Compuestos antifungicos.
NO20064519L (no) Karbolinderivater som er anvendbare ved inhibering av angiogenese
NO20082089L (no) Fosfatidylinositol 3-kinaseinhibitorer og deres anvendelse
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA201170735A1 (ru) Производные бензотиазола в качестве средств против рака
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20090295L (no) Substituerte heteroarylderivater
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
UA107951C2 (xx) Похідні імідазопіридину як інгібітори jak
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
EA201990833A1 (ru) Соединение пиридина
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
SMP201000124B (it) Derivati di chinoline e chinossaline come inibitori di proteina tirosina chinasi
MX2015014204A (es) Compuestos de pirimidinio sustituido y derivados para combatir plagas de animales.
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application